Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.55 |
| ▸ | METAP1 | P53582 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | CYP24A1 | Q07973 | 4/20 | 0.44 |
| ▸ | CYP27A1 | Q02318 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714800 | 1.00 | ACHE (0.56) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL2440274 | 0.88 | CYP24A1 (0.56) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL1180262 | 0.84 | ACHE (0.69) | ACHECYP19A1METAP1ALDH1A1 | |
| SCHEMBL5237018 | 0.83 | ACHE (0.71) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL5237012 | 0.83 | ACHE (0.71) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL5237022 | 0.83 | ACHE (0.71) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL6630846 | 0.81 | ACHE (0.56) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL31040171 | 0.81 | CYP19A1 (0.59) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL992002 | 0.81 | ACHE (0.56) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL13363970 | 0.81 | ACHE (0.56) | ACHECYP19A1METAP1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567321-A | Preparation method of 7-methoxy naphthalene acetonitrile | 湖南省湘中制药有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1761513-A1 | TETRACYCLIC COMPOUNDS AS ESTROGEN LIGANDS | Wyeth (US) | 2007-03-14 | — | — | EP | disclosed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2006007503-A1 | TETRACYCLIC COMPOUNDS AS ESTROGEN LIGANDS | WYETH (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20060004087-A1 | Tetracyclic compounds as estrogen ligands | WYETH (US) | 2006-01-05 | — | — | US | disclosed |
| US-20040267017-A1 | 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-12-30 | — | — | US | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-0313295-B1 | SUBSTITUTED TETRALINS, CHROMANS AND RELATED COMPOUNDS IN THE TREATMENT OF ASTHMA, ARTHRITIS AND RELATED DISEASES | PFIZER INC. (US) | 1993-07-28 | — | — | EP | disclosed |
| US-5059609-A | Lipoxygenase inhibitors; leukotriene receptor blockers; psoriasis; antiulcer agents and myocardial infarctions | PFIZER INC. (US) | 1991-10-22 | — | — | US | disclosed |
| WO-1989003681-A1 | SUBSTITUTED TETRALINS, CHROMANS AND RELATED COMPOUNDS IN THE TREATMENT OF ASTHMA | PFIZER INC. (US) | 1989-05-05 | — | — | WO | disclosed |
| EP-0313295-A2 | Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases | PFIZER INC. (US) | 1989-04-26 | — | — | EP | disclosed |
| EP-0313296-A2 | Substituted chromans and related compounds in the treatment of asthma | PFIZER INC. (US) | 1989-04-26 | — | — | EP | disclosed |
| US-4602022-A | VASODILATORS, ANTIAGGREGANT AGENTS, ANTIINFLAMMATORY AND HYPOTENSIVE AGENTS | FARMITALIA CARLO ERBA, S.P.A. (IT) | 1986-07-22 | — | — | US | disclosed |
| US-4588738-A | N-imidazolyl derivatives of 1,2,3,4-tetrahydro-naphthalene and indan as platelet aggregation inhibitors | FARMITALIA CARLO ERBA S.P.A. (IT) | 1986-05-13 | — | — | US | disclosed |
| US-4510149-A | VASODILATORS, HYPOTENSIVE AGENTS, ANTIARTHRITIC AGENTS | FARMITALIA CARLO ERBA S.P.A. (IT) | 1985-04-09 | — | — | US | disclosed |
| US-4492707-A | ANTILIPEMIC AGENT | FARMITALIA CARLO ERBA S.P.A. (IT) | 1985-01-08 | — | — | US | disclosed |
| US-3932430-A | Substituted indeno, naphtho and cyclohepta pyrazoles | SANDOZ, INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004087-A1 | Tetracyclic compounds as estrogen ligands | ESR1, ESRRA, ESR2 | ACHE 2610/4885CYP19A1 18/4885METAP1 4021/4885 |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | TNF, LITAF, MAPK1 | ACHE 4124/4885CYP19A1 793/4885METAP1 2921/4885 |
| US-20040267017-A1 | 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors | CYP17A1, CYP21A2, HSD17B1 | ACHE 2039/4885CYP19A1 7/4885METAP1 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.